# **CEO Presentation to the CCRHB**

19 July 2019

James K. Gilman, MD NIH CC CEO

## It's Halftime – What's the Score?

 'Another "heads up" – we have always appointed Institute and Center Directors (and equivalents) on indefinite T42 appointments. The passage of the 21<sup>st</sup> Century Cures Act ..... now make it necessary for us to appoint ICDs on 5year, renewable, term appointments... ...You will be the <u>first</u> new appointment under this new system, and HR will be sending you a note to that effect.'

Larry (4 January 2017)


## **Indications that We are Better**

- 7 x 24 (great work by the CCND Administrative Coordinators)
- Significantly less use of the term 'ancillary' to refer to a staff member or group
- Elevated the importance of Staff Clinicians, Mid-Level Providers, and Nurses
- We are getting really good at doing FMEA's
- Risk-based decision making we have said no and been supported
- We don't look the other way
- Budget for equipment and facility modification much improved

## **Still Need Improvement**

- Although rare, still see instances when interest in patient wanes after the interests of science have been satisfied
- Professionalism and civility in communication
- Facilities and infrastructure
- Still finding our way in the intersection of cGMP and a grievously ill patient with few options

### Average Daily Census as of July 1, 2019



#### ADC Stats • 3-Year Average (FY 2015-2017) = 126.6 • Year End FY 2018: 113.9 • Year-to-Date FY 2019 (as of 07/01/2019): 113.0

## **Dr. David Henderson Stepping Down**



- 40 Years at the NIH
- First Hospital Epidemiologist at the CC
- 25 Years as Deputy Director for Clinical Care
- Incoming President of Society for Healthcare Epidemiology of America (SHEA)
- 2019 Recipient of Alvan R. Feinstein Award in Clinical Epidemiology from the American College of Physicians
- 2019 Recognition as Distinguished Alumnus of University of Chicago School of Medicine

Effective Date – 31 December 2019 Search Committee Already Named Title Change – Chief Medical Officer



## **Evolution of the Document**

- First started summer of 2017
- Re-start summer of 2018 one full budget cycle, 18 mos of CCGB meetings, 2 institute planning cycles, 3 dozen IC meetings (or more), 3 dozen or more MEC meetings, at least a few Hill encounters
- 7 x 2 hour meetings at the Cloisters involving 30 attendees from the CC
- Drafted Jan / Feb / March of this year text reviewed several times in the CC
- Submitted to Division of Program Coordination, Planning, and Strategic Initiatives for review – passed back with a number of recommendations

### Context

- High level strategic plan, not a detailed implementation plan
- Must serve external stakeholders, such as elected and appointed officials but also inform members of the IRP as well
- Without dwelling on the recent past too much, acknowledge the reality the need for change in the CC after the Red Team



- Continuing to lead the world in conducting first-in-human clinical research while maintaining our focus on rare and refractory diseases
- This is the wheelhouse of the "House of Hope"
- Implementation CCE, new Blood & Inherited Diseases Cellular Therapy Program, etc.

## **Aim #2**

- Increasing the use of the CC by the NIH IRP while simultaneously accelerating the CC's status as a national resource for the extramural community
- Space management / allocation / attempts to find room for new programs
- Acknowledging the contributions of the legacy UO1 program and encouraging newer models, if the CC is to be relevant outside the Bethesda campus, virtual connections need to be expanded – including the use of telehealth and telemedicine



- Demonstrating profound respect for our patients, whom we recognize as our full partners in the clinical research enterprise
- New members on the Patient Advisory Group (PAG)
- Providing resources for suggestions that come out of the PAG
- CSO evaluating how to incorporate patients, family members, advocates into clinical research efforts



- Partnering with the ICs to recruit, develop, and retain the next generation of great NIH clinical researchers and the CC staff that will support their efforts
- Key IC representatives on every key search
- Increased support to MRSP and management fellowships
- Talent management council

### Friday, July 19, 2019 OPEN SESSION

9:00 AM – 9:45AM	Board Members' Tour: National Institutes of Health (NIH) Clinical Center Building 10
10:00 AM	Welcome & Board Chair's Overview <ul> <li>Laura Forese, MD, NewYork-Presbyterian, and Hospital Board Chair</li> </ul>
10:05AM	NIH Director's Remarks Francis Collins, MD, PhD, Director, NIH
10:20 AM	Clinical Center Facilities Update Mr. Dan Wheeland, Director, NIH Office of Research Facilities
11:00 AM	NIH CC CEO Update > James Gilman, MD, Chief Executive Officer, NIH Clinical Center
12:00 PM	Discussion
12:20 PM	Lunch
1:20 PM	NIH IRBs > Jonathan M Green, MD MBA, Director, Office of Human Subjects Research Protections
2:20 PM	Patient Safety & Clinical Quality Update > Laura Lee, MS, RN, Director, Clinical Center Office of Patient Safety & Clinical Quality
3:00 PM	Adjournment



"Thank you to all who make our vital mission possible: dedicated staff and trainees, the public, and most importantly our patients. Patients are the heart of everything we do. As seen in the 2017 Discovery documentary: First in Human, the medicine of tomorrow starts today. It starts at the NIH Clinical Center. It starts with you."